Arch. Pharm. (Weinheim) 317, 038-041 (1984)

Preparation of 1-(Aroylalkyl)-1*H*-imidazole and -Benzimidazole Derivatives of Pharmaceutical Interest. A New Synthetic Procedure

Roberto Pellicciari*)**, Massimo Curini*** and Nicoletta Spagnoli***

** Istituto di Chimica Farmaceutica e Tecnica Farmaceutica, Università degli Studi, Perugia, Italy

*** Istituto di Chimica Organica, Facoltà di Farmacia, Università degli Studi, Perugia, Italy Eingegangen am 22. November 1982

A simple and improved procedure for the preparation of the title compounds is described. It is based on the copper-bronze catalyzed decomposition of aryl diazo ketones in the presence of imidazolic substrates.

Herstellung von 1-(Aroylalkyl)-1*H*-Imidazol- und Benzimidazol-Derivaten von pharmazeutischem Interesse. Ein neues synthetisches Verfahren

Wir beschreiben ein vereinfachtes, verbessertes Verfahren zur Herstellung der Titelverbindungen. Das Verfahren beruht auf der Kupfer-katalysierten Thermolyse von Aryldiazoketonen in Anwesenheit von Imidazolen.

N-Substituted phenethylimidazoles of type I have shown to display a variety of pharmacological activities¹). Among the compounds of this group, miconazole $(1)^{2}$ is currently used in the treatment of systemic fungal infections, while potent anticonvulsant activity has been demonstrated for a large number of 1-(2-naphthoylmethyl)-1*H*-imidazoles among which **9a** was selected as a particularly promising anticonvulsant agent^{3a-c)}.

The known methods for the preparation of the parent α -arylimidazole-1-ethanol **(Ib)** involve the initial N-alkylation of the imidazole nucleus with 2-halo-methylarylketones in the presence of alkaline reagents⁴⁾ followed by the reduction of the imidazole N-aroylalkylderivative thus formed. The crucial N-alkylation step, however, does not proceed satisfactorily due to the recovery of large amounts of the starting imidazole and the formation of relevant amounts of 1,3-bis(phenacyl)imidazolium halides as by-products⁴⁾.

We have recently reported that imidazole (3), reacts with diazoesters in presence of copper-bronze as catalyst, to give the corresponding N-carboalkoxymethyl derivatives in high yield⁵⁾. Continued interest in this class of compounds made us turn attention to the applicability of the method to the synthesis of 1-(aroylmethyl)-imidazole derivatives of general structure **Ia**. When diazoacetophenone (2) was allowed to react with imidazole (3) in the presence of copper-bronze as catalyst, 1-phenacylimidazole (4) was obtained as the only reaction product in 76 % yield. Analogously, the reaction of diazoacetophenone with benzimidazole (5) yielded 1-phenacyl-benzimidazole (6a) in 60 % yield.

C1

1

C







6a: R + R' = O **b:** R = H, R' = OH



The reaction was applied, moreover, as a key step in a new synthesis of the anticonvulsant 1-(-2-naphtylmethyl)imidazole derivatives **9a** and **9b**. Successive exposure of 2-naphthoic acid to oxalyl chloride and diazomethane led to the diazo ketone **8**. Decomposition of the diazo compound in a xylene solution of imidazole in the presence of copper-bronze at 85°, produced 1-(-2-naphtoylmethyl)imidazole (**9a**) in 60% yield. α -Arylimidazole-1-ethanol derivatives of general type **Ib** can be easily obtained by sodium borohydride reduction of the corresponding ketoderivatives⁶). By applying this procedure to **9a** and **6a** we have obtained in high yields 1-(-2-hydroxy-2-naphthylethyl)imidazole (**9b**) and 1-(-2-hydroxy-2-phenylethyl)benzimidazole (**6b**), respectively.

Further exploitations of the methods above described for the preparation of products of pharmaceutical interest is under process in our laboratory.

The authors acknowledge financial support from "Ministero della Pubblica Istruzione", Italy.

Experimental Part

MP: Kofler microscope (uncorr.). IR Spectra: Beckmann Acculab 5 spectrophotometer. ¹H-NMR Spectra: Varian EM 390 spectrometer. Column Chromatography: Kieselgel 60 (Merck), neutral alumina (Woelm). Elementary analyses: automatic analyzer, Model 1102, Carlo Erba (Italy).

I-Phenacyl-imidazole (4)

A solution of 1.07 g (7.3 mmol) diazoacetophenone (2)⁷⁾, and 0.28 g (4 mmol) imidazole (3) in 10 ml anhydrous xylene, is added over 5 h to a stirred mixture of 0.28 g (4 mmol) imidazole and 0.06 g copper bronze in 5 ml xylene at 85 °C and the mixture is stirred at 85 °C for 13 h. It is then filtered and the filtrate evaporated under reduced pressure. Chromatography of the residue (1.5 g) on silica gel and elution with chloroform/methanol (49:1) gives 0.9 g of 4, m.p. 117–118 °C (benzene) (lit.⁸⁾ 117–118 °C) (yield 76 %). IR (CHCl₃): 1690 cm⁻¹ (C=O); ¹H-NMR (CDCl₃): δ (ppm) = 5.4 (s, 2H, -COCH₂-), 7.1–8.2 (m, 8H, aromatic protons). C₁₁H₁₀N₂O (186.2) Calcd: C 71.0 H 5.41 N 15.1; Found: C 71.0 H 5.38 N 15.0. Finally, further elution with the same solvent gives unreacted, excess imidazole (0.22 g).

1-Phenacylbenzimidazole (6a)

A solution of 0.6 g (4 mmol) 2 in 10 ml anhydrous xylene is added over a 5 h period to a stirred mixture of 0.69 g (5 mmol) benzimidazole (5) and 0.05 g copper-bronze in 10 ml xylene at 90 °C and the mixture is stirred at 90 °C for 24 h. It is then filtered and the filtrate evaporated under reduced pressure. Chromatography of the residue (1.1 g) on silica gel and elution with chloroform/methanol (49:1) gives 0.58 g 6a, m.p. 75–80 °C, (yield 60 %). IR (CHCl₃): 1690 cm⁻¹ (C=O); 'H-NMR (CDCl₃): δ (ppm) = 5.5 (s, 2H₃-COCH₂-), 7.1–8.2 (m, 10 H, aromatic protons). C₁₅H₁₂N₂O (236.26). Calcd: C 76.3 H 5.12 N 11.9; Found C 77.0 H 5.01 N 11.7. Finally, further elution with the same solvent gives unreacted excess 5 (0.2 g).

2-Diazoacetylnaphthalene (8)⁹⁾

1 g (5.8 mmol) 2-naphthoic acid (7) was added to 6 ml freshly distilled oxalyl chloride. The frothing mixture was stirred for 4 h, and then the excess of oxalyl chloride was removed i. vac. dist. A solution of the resulting crystalline acid chloride in 50 ml dry ether was added dropwise during 4 h to an ice-cold, well stirred ethereal solution of 15 mmol diazomethane and 0.585 g (5.8 mmol) triethyl-amine. The mixture was stirred at 0 °C for additional 4 h and kept at room temp. for 12 h. The mixture was then filtered and the excess of diazomethane was blown off under a stream of nitrogen and the solution concentrated to give 0.650 g of **8**, mp 73–75 °C (light petroleum/ether) (yield 64 %). IR (CHCl₃): 2110 (N₂CH), 1620 cm⁻¹ (C=O). 'H-NMR (CDCl₃): δ (ppm) = 5.5 (s, 1H, COCHN₂) 7–8 (m, 7H, aromatic protons).

1-(2-Naphthoylmethyl)imidazole (9a)

A solution of 0.6 g (3 mmol) 1-(diazoacetyl)naphthalene (8) in 50 ml anhydrous xylene is added over 5 h period to a stirred mixture of 0.34 g (5 mmol) imidazole (3) and 0.6 g copper-bronze in 10 ml xylene

at 85 °C and the mixture is stirred at 85 °C for 16 h. It is then filtered and the filtrate evaporated under reduced pressure. Chromatography of the residue (0.9 g) on neutral alumina (activity IV) and elution with chloroform/methanol (49:1) gives 0.5 g of **9a**, mp 225–227 °C (lit.^{3a)} 226–228.5 °C) (yield 69 %). IR (CHCl₃): 1690 cm⁻¹ (C=O); 'H-NMR (CDCl₃) δ (ppm) = 5.4 (s, 2H, CHCH₂-), 7.2–8.5 (m, 10 H, aromatic protons). C₁₅H₁₂N₂O (236.26) Calcd: C 76.3 H 5.12 N 11.9; Found C 76.9 H 5.09 N 11.8.

NaBH₄ reduction of 1-phenacyl-benzimidazole (6a) to 6b

A solution of 31 mg NaBH₄ in 5 ml ethanol is added dropwise to a stirred solution of 200 mg **6a** in 10 ml ethanol at 0 °C. Stirring is continued at room temp. for 1 h. Usual work up and chromatography of the residue (200 mg) on silica gel and elution with chloroform/methanol (9:1) gives 170 mg of **6b**, mp 106–108 °C (chloroform/light petroleum) (lit.¹⁰⁾ 106–107 °C) (yield 87 %). ¹H-NMR (CDCl₃): δ (ppm) = 4.2 (m, 2H, -CH(OH)<u>CH₂-</u>), 5 (m, 1H, -<u>CH(OH)-CH₂-</u>); 6.9–7.5 (m, 10H, aromatic protons). C₁₅H₁₄N₂O (238). Calcd: C 76.3 H 5.12 N 11.9; Found C 76.6 H 5.01 N 11.3.

NaBH₄ reduction of 1-(2-naphthoylmethyl)imidazole (9a) to 9b

A solution of 66 mg NaBH₄ in 10 ml ethanol is added dropwise to a stirred solution of 300 mg 9a in 20 ml ethanol at 0 °C. Stirring is continued at room temp. for 1 h. Usual work up and chromatography of the residue (280 mg) on silica gel and elution with chloroform/methanol (9:1) gives 260 mg of 9b, mp 155–158 °C) (lit.^{3a)} 156–160 °C), (yield 86%). 'H-NMR (CDCl₃): δ (ppm) = 4.3 (m, 2H, -CH(OH)CH₂-, 5.2 (m, 1H, -CH(OH)CH₂-), 7.2–7.9 (m, 10 H, aromatic protons). C₁₅H₁₄N₂O (238); Calcd: C 76.3 H 5.12 N 11.9; Found: C 76.4 H 5.1 N 11.6.

References

- 1 See e.g.: J.A. Katzenellenbogen, R.J. McGorrin, T. Tatee, R.J. Kempton, K.E. Karlson and D.H. Kinder, J. Med. Chem. 24, 435 (1981) and references therein.
- 2 a) J. van Cutsen and D. Thienpont, Chemotherapy 17, 392 (1972); b) P.A.J. Janssen and W. vanBever in Pharmacological and Biochemical Properties of Drug Substances, p. 333, M.E. Goldberg, Ed., publ. Am. Pharm. Ass., Acad. Pharm. Sci., Washington 1979.
- 3 a) A.M. Walker, M.B. Wallach and D.R. Hirschfeld, J. Med. Chem. 24, 67 (1981); b) M.B.
 Wallach, L.R. Hedley, K.E. Peterson and C. Rogers, Fed. Proc. Fed. Am. Soc. Exp. Biol. 39, 316 (1980); c) D. Nardi, A. Tajana, A. Leonardi, R. Pennini, F. Portioli, M.J. Magistretti and A. Subissi, J. Med. Chem. 24, 727 (1981) and references therein.
- 4 J. Brian Jones and D. W. Hysert, Can. J. Chem. 49, 3012 (1971).
- 5 R. Pellicciari, M. Curini, N. Spagnoli and P. Ceccherelli, Synthesis 1981, 629; for related work in the imidazole area see: R. Pellicciari, M.C. Fioretti, P. Cogolli and M. Tiecco, Arzneim. Forsch. 30, 2103 (1980).
- 6 E.F. Godefroi, J. Heeres, J. Van Cutsem and P.A.J. Janssen, J. Med. Chem. 12, 784 (1969).
- 7 L.T. Scott and M.A. Minton, J. Org. Chem. 42, 3757 (1977).
- 8 Beilstein Handbuch der Organischen Chemie, Vol. 48, II, p. 37, Springer-Verlag, Berlin-Göttingen-Heidelberg 1954.
- 9 For an analogous procedure see: V. Lee and M.S. Newman, Org. Synth., Vol. 50, p. 77.
- 10 G. Cooper and W. J. Irwin, J. Chem. Soc. Perkin Trans. 1 1976, 545.

[Ph 698]